Corleen M. Roche is the Chief Financial Officer at Immunome.
Corleen's mailing address filed with the SEC is C/O IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON, PA, 19341.
Over the last 4 years, insiders at Immunome have traded over $0 worth of Immunome stock and bought 480,004 units worth $5,722,735 . The most active insiders traders include Clay B Siegall, Jean Jacques Bienaime und Michael Rapp. On average, Immunome executives and independent directors trade stock every 84 days with the average trade being worth of $518,362. The most recent stock trade was executed by Jean Jacques Bienaime on 15 August 2024, trading 7,000 units of IMNM stock currently worth $97,580.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Immunome executives and other stock owners filed with the SEC include: